Omnicell (OMCL)
(Delayed Data from NSDQ)
$29.31 USD
+0.02 (0.07%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $29.55 +0.24 (0.82%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.31 USD
+0.02 (0.07%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $29.55 +0.24 (0.82%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth F Momentum C VGM
Zacks News
CPSI or OMCL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?
CPSI or OMCL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?
Why You Shouldn't Bet Against Omnicell (OMCL) Stock
by Zacks Equity Research
Omnicell (OMCL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why Is Omnicell (OMCL) Down 5% Since Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Omnicell (OMCL) on its strong segmental performance in Q4.
Omnicell-Geisinger Deal Improves Patient Care via Automation
by Zacks Equity Research
Omnicell's (OMCL) XT series Automated Dispensing Systems partners with Geisinger to streamline nursing workflow and improve patient care.
Omnicell (OMCL) Lags Q4 Earnings Estimates, Beats on Revenues
by Zacks Equity Research
Omnicell (OMCL) fourth-quarter 2019 results reflect strong segmental performances.
Omnicell (OMCL) Misses Q4 Earnings Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of -1.28% and 2.20%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hill-Rom (HRC) Gains Ground on Global Expansion, New Menu
by Zacks Equity Research
Hill-Rom (HRC) is optimistic about its latest buyouts of Breathe Technologies and Voalte, mirroring its outstanding capital management strategy in turn.
Here's Why You Should Retain Edwards Lifesciences Stock Now
by Zacks Equity Research
Investors can hold on to Edwards Lifesciences (EW) in their portfolio for now, thanks to solid prospects.
Hologic (HOLX) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Hologic (HOLX) gains from several positive developments.
Integra Announces Preliminary Q4 Results, Share Buyback Plan
by Zacks Equity Research
Integra (IART) projects fourth-quarter 2019 revenues at or near the low end of its previously-announced guidance.
Here's Why You Should Add Bruker (BRKR) to Your Portfolio Now
by Zacks Equity Research
Investor confidence in Bruker (BRKR) is at a high, thanks to solid prospects.
5 Promising Growth Stocks in MedTech to Invest in 2020
by Trina Mukherjee
We have zeroed in on five impressive growth stocks in MedTech on the back of the industry's lucrative prospects.
Invest in These 5 Low Leverage Stocks Before Q4 Earnings
by Zacks Equity Research
Companies displaying high earnings growth along with high leverage ratios should be avoided while making investment decisions. So, investors should select companies with low leverage.
Varian (VAR) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Varian (VAR) gains from several positive developments.
Amedisys Gains on Favorable Demography, New Hospice Buyouts
by Zacks Equity Research
Amedisys (AMED) is steadily benefiting from its recent takeovers of hospice care providers, namely RoseRock Healthcare and Compassionate Care Hospice.
Exact Sciences Rides on Cologuard, Eyes Merger Synergies
by Zacks Equity Research
Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.
Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging
by Zacks Equity Research
The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.
Here's Why You Should Add STERIS (STE) to Portfolio Now
by Zacks Equity Research
Investor confidence is high on STERIS (STE) stock for now, thanks to its solid prospects.
LabCorp (LH) Grows on Solid Diagnostics Arm Despite PAMA Headwinds
by Urmimala Biswas
LabCorp's (LH) Diagnostics business flourishes organically in terms of both revenues and volumes despite additional price reductions due to Protecting Access to Medicare Act (PAMA).
Here's Why You Should Hold on to Phibro (PAHC) Stock Now
by Zacks Equity Research
Investors can retain Phibro (PAHC) stock for now, thanks to its solid prospects.
Illumina Stock Slips on Pacific Biosciences Deal Termination
by Zacks Equity Research
Per Illumina (ILMN), the lengthy route to achieve regulatory nods for the transaction induces uncertainty about the ultimate outcome of the integration.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now
by Zacks Equity Research
Investors can retain QIAGEN (QGEN) stock for now, thanks to its solid prospects.